Technical Analysis for BCAX - Bicara Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 1.80% | |
| Lower Bollinger Band Walk | Weakness | 1.80% | |
| New 52 Week Low | Weakness | 1.80% | |
| Wide Bands | Range Expansion | 1.80% | |
| Below Lower BB | Weakness | 1.80% | |
| Lower Bollinger Band Touch | Weakness | 1.80% | |
| Oversold Stochastic | Weakness | 1.80% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 21 hours ago |
| Rose Above Lower Bollinger Band | about 21 hours ago |
| Up 5% | about 21 hours ago |
| Up 3% | about 21 hours ago |
| Down 1% | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Antibodies Tumor Cancer Immunotherapy Specialty Drugs Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Antibodies Tumor Cancer Immunotherapy Specialty Drugs Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Tumor Microenvironment
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.08 |
| 52 Week Low | 17.465 |
| Average Volume | 356,058 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 22.85 |
| 20-Day Moving Average | 22.12 |
| 10-Day Moving Average | 20.36 |
| Average True Range | 1.85 |
| RSI (14) | 29.08 |
| ADX | 22.22 |
| +DI | 10.81 |
| -DI | 21.48 |
| Chandelier Exit (Long, 3 ATRs) | 22.53 |
| Chandelier Exit (Short, 3 ATRs) | 23.01 |
| Upper Bollinger Bands | 26.80 |
| Lower Bollinger Band | 17.44 |
| Percent B (%b) | 0.07 |
| BandWidth | 42.34 |
| MACD Line | -1.36 |
| MACD Signal Line | -0.82 |
| MACD Histogram | -0.5359 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.83 | ||||
| Resistance 3 (R3) | 19.83 | 19.25 | 19.54 | ||
| Resistance 2 (R2) | 19.25 | 18.81 | 19.25 | 19.44 | |
| Resistance 1 (R1) | 18.67 | 18.53 | 18.96 | 18.67 | 19.35 |
| Pivot Point | 18.09 | 18.09 | 18.24 | 18.09 | 18.09 |
| Support 1 (S1) | 17.51 | 17.65 | 17.80 | 17.51 | 16.83 |
| Support 2 (S2) | 16.93 | 17.37 | 16.93 | 16.74 | |
| Support 3 (S3) | 16.35 | 16.93 | 16.64 | ||
| Support 4 (S4) | 16.35 |
